Ram Selvaraju


Protalix Biotherapeutics Inc Fabry Disease Pivotal Program Shows Encouraging Potential: Rodman & Renshaw

Protalix Biotherapeutics Inc (NYSEMKT:PLX) investors are getting skittish today, sending shares on a roughly 5% whirl down despite the biotech firm posting a …

Ocular Therapeutix Inc (OCUL) Gets A Bullish Vote Following 2Q:17 Update

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are on a roughly 4% dip today after the biotech firm released second-quarter financial results- a quarter that …

H.C. Wainwright Takes Ocular Therapeutix Inc’s (OCUL) Restructuring Plan in Bullish Stride as Shares Dip 5%

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are sliding almost 5% today on the heels of the biotech firm’s President and CEO Antony Mattessich  new …

Rodman & Renshaw Roots for Synergy Pharmaceuticals Inc. (SGYP) Ahead of Promising Commercial Trajectory for Trulance

Last week, Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) excited investors with the news that its drug Trulance, a treatment approved in the indication of Chronic …

Synergy Pharmaceuticals Inc (SGYP) Gains Upper Hand in IBS-C Arena

Believing Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) odds in the IBS-C competitive arena just got better, Rodman & Renshaw analyst Ram Selvaraju reiterates a Buy …

Rodman & Renshaw’s Ram Selvaraju Confident on Synergy Pharmaceuticals Inc (SGYP) Following SNDA Submission

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares are rising almost 3% today after the biotech firm made waves filing the supplemental New Drug Application (sNDA) …

Rodman & Renshaw Cuts Price Target on Valeant Pharmaceuticals Intl Inc (VRX) as Revenue Attrition Will Yield a Significant Impace

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares are sinking almost 5% following the release of financial guidance that paints a murky picture for the …